Esketamine clinical trials: reply to Maju et al.
Epidemiol Psychiatr Sci
; 29: e122, 2020 Apr 29.
Article
in En
| MEDLINE
| ID: mdl-32345395
Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Depressive Disorder, Treatment-Resistant
/
Ketamine
/
Antidepressive Agents
Type of study:
Clinical_trials
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Epidemiol Psychiatr Sci
Year:
2020
Document type:
Article
Affiliation country:
Italy
Country of publication:
United kingdom